OBJECTIVES: Describe the prevalence of contraindications to chronic hepatitis C (CHC) treatment among CHC patients not receiving CHC treatment (direct-acting antiviral [DAA] protease inhibitors, peg-interferon alpha, or ribavirin).  METHODS: Adult patients with ≥2 CHC diagnoses (ICD-9-CM codes 070.44, 070.54, 070.70, 070.71) and no DAA fills at any time in their claims history were selected from a de-identified US-based claims database (2010-2012); the first CHC diagnosis after 5/13/2011 was defined as the index date. Patients with CHC treatment 6-months before or 12 months after the index date were excluded. All patients were required to have continuous eligibility and no claims for hepatitis B during the 6-months before (baseline) and 12-months after their index dates. Contraindications (based on a World Health Organization hepatitis C guide) during the baseline period were identified based on ICD-9 codes and described for the overall cohort as well as stratified by age (18-39; 40-49; 50-59; 60-69; 70-79; 80+).  RESULTS: There were